Cargando…
Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures
OBJECTIVES: Anti-osteoporotic drugs (AOD) are essential for secondary prevention of osteoporotic fracture (OF) in patients with established osteoporosis. However, data about AOD utilization rates are scarce among patients with OF. This study was therefore aimed at determining the AOD utilization rat...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rambam Health Care Campus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345764/ https://www.ncbi.nlm.nih.gov/pubmed/35701156 http://dx.doi.org/10.5041/RMMJ.10473 |
_version_ | 1784761502851399680 |
---|---|
author | Aypak, Cenk Bircan, Mustafa A. Özdemir, Ayşe |
author_facet | Aypak, Cenk Bircan, Mustafa A. Özdemir, Ayşe |
author_sort | Aypak, Cenk |
collection | PubMed |
description | OBJECTIVES: Anti-osteoporotic drugs (AOD) are essential for secondary prevention of osteoporotic fracture (OF) in patients with established osteoporosis. However, data about AOD utilization rates are scarce among patients with OF. This study was therefore aimed at determining the AOD utilization rates among those particularly vulnerable patients. MATERIALS AND METHODS: This cross-sectional study followed the medical records of patients with OF starting from their first OF diagnosis date. Each patient’s preventive osteoporosis treatments (vitamin D, calcium+vitamin D) and AOD utilization rate were recorded for a 12-month period following OF diagnosis. RESULTS: A total of 210 patients (168 females, mean age: 67.8±11.9 years; 42 males, mean age 62.4±16.1 years) were enrolled in the study. Of these, 65.7% (n=138) did not use any medication for primary protection against osteoporosis before OF diagnosis. The ratio of patients not using any type of medication for secondary prevention after OF increased from 26.5% to 51% during a 12-month period. In addition, by one year following diagnosis, AOD usage rate had decreased from 62.3% to 41.3%. CONCLUSION: The AOD usage rates for secondary prevention of OF were insufficient, and cessation rates were high. Identification of factors associated with decreased AOD utility rates will provide important information for guiding patient follow-up in order to reduce the occurrence of OF. |
format | Online Article Text |
id | pubmed-9345764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Rambam Health Care Campus |
record_format | MEDLINE/PubMed |
spelling | pubmed-93457642022-08-11 Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures Aypak, Cenk Bircan, Mustafa A. Özdemir, Ayşe Rambam Maimonides Med J Original Research OBJECTIVES: Anti-osteoporotic drugs (AOD) are essential for secondary prevention of osteoporotic fracture (OF) in patients with established osteoporosis. However, data about AOD utilization rates are scarce among patients with OF. This study was therefore aimed at determining the AOD utilization rates among those particularly vulnerable patients. MATERIALS AND METHODS: This cross-sectional study followed the medical records of patients with OF starting from their first OF diagnosis date. Each patient’s preventive osteoporosis treatments (vitamin D, calcium+vitamin D) and AOD utilization rate were recorded for a 12-month period following OF diagnosis. RESULTS: A total of 210 patients (168 females, mean age: 67.8±11.9 years; 42 males, mean age 62.4±16.1 years) were enrolled in the study. Of these, 65.7% (n=138) did not use any medication for primary protection against osteoporosis before OF diagnosis. The ratio of patients not using any type of medication for secondary prevention after OF increased from 26.5% to 51% during a 12-month period. In addition, by one year following diagnosis, AOD usage rate had decreased from 62.3% to 41.3%. CONCLUSION: The AOD usage rates for secondary prevention of OF were insufficient, and cessation rates were high. Identification of factors associated with decreased AOD utility rates will provide important information for guiding patient follow-up in order to reduce the occurrence of OF. Rambam Health Care Campus 2022-07-31 /pmc/articles/PMC9345764/ /pubmed/35701156 http://dx.doi.org/10.5041/RMMJ.10473 Text en Copyright: © 2022 Aypak et al https://creativecommons.org/licenses/by/3.0/This is an open-access article. All its content, except where otherwise noted, is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0 (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Aypak, Cenk Bircan, Mustafa A. Özdemir, Ayşe Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures |
title | Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures |
title_full | Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures |
title_fullStr | Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures |
title_full_unstemmed | Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures |
title_short | Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures |
title_sort | anti-osteoporotic drug utilization rates for secondary prevention among patients with osteoporotic fractures |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345764/ https://www.ncbi.nlm.nih.gov/pubmed/35701156 http://dx.doi.org/10.5041/RMMJ.10473 |
work_keys_str_mv | AT aypakcenk antiosteoporoticdrugutilizationratesforsecondarypreventionamongpatientswithosteoporoticfractures AT bircanmustafaa antiosteoporoticdrugutilizationratesforsecondarypreventionamongpatientswithosteoporoticfractures AT ozdemirayse antiosteoporoticdrugutilizationratesforsecondarypreventionamongpatientswithosteoporoticfractures |